Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

July 18, 2019

AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs

AIDS Healthcare Foundation (AHF) is calling on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, to set up a $10 billion victim compensation fund for patients harmed after taking the drug maker’s TDF-based (tenofovir disoproxil fumarate) drugs as part of their treatment for HIV or AIDS or taken by uninfected individuals as part of the HIV prevention strategy known as pre-exposure prophylaxis or PrEP.

AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs